GLP-1 Science
What Is a GLP-1 Receptor Agonist? A Simple Explanation
GLP-1 receptor agonists are drugs that mimic the fullness hormone GLP-1. Ozempic, Wegovy, and Mounjaro are all in this c...
In August 2023, the SELECT trial results were published in the New England Journal of Medicine. They showed that semaglutide 2.4 mg (Wegovy) reduced the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% in overweight and obese patients with established cardiovascular disease but without diabetes.
This result changed the conversation about GLP-1 agonists. They were already established as effective weight loss medications. SELECT proved they are also cardiovascular protective drugs — independently of whether the patient has diabetes.
The SELECT Trial: What It Was and What It Found
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) enrolled 17,604 patients across 41 countries. All participants had:
- BMI of 27 or higher (overweight or obese)
- Established cardiovascular disease (prior heart attack or stroke, or symptomatic peripheral artery disease)
- No type 2 diabetes diagnosis
Participants received either semaglutide 2.4 mg weekly or placebo and were followed for approximately 5 years.
Results:
- Major adverse cardiovascular events (MACE): 6.5% in semaglutide group vs 8.0% in placebo — a 20% relative risk reduction
- Non-fatal heart attack: 28% lower in semaglutide group
- Cardiovascular death: 15% lower (not statistically significant alone but contributing to overall MACE reduction)
The reduction in cardiovascular events appeared to begin within the first year of treatment — faster than could be explained by weight loss alone — suggesting direct cardiovascular effects of GLP-1 receptor activation beyond metabolic improvement.
Why Does GLP-1 Protect the Heart?
Several mechanisms contribute:
Indirect: weight and metabolic improvement. Significant weight loss (average 9.4% in SELECT) reduces blood pressure, improves lipids, reduces inflammatory markers, and decreases the mechanical load on the heart. These metabolic improvements reduce cardiovascular risk over time.
Direct: GLP-1 receptors on the heart. GLP-1 receptors are expressed in cardiac muscle, coronary arteries, and the cardiac conduction system. Direct receptor activation in these tissues may reduce cardiac inflammation, improve coronary blood flow, and enhance cardiomyocyte function.
Direct: anti-inflammatory effects. GLP-1 receptor agonists reduce circulating C-reactive protein (CRP) and other inflammatory markers — beyond what weight loss alone explains. Chronic low-grade inflammation is a major driver of atherosclerosis and cardiovascular events.
Direct: endothelial function. GLP-1 receptor activation improves endothelial function — the ability of blood vessel walls to dilate and regulate blood flow — which reduces the endothelial dysfunction underlying atherosclerotic plaque progression.
Earlier Evidence: The SUSTAIN-6 Trial
The SUSTAIN-6 trial (in type 2 diabetic patients) showed semaglutide 1 mg reduced MACE by 26%. The SELECT trial extended this finding to non-diabetic patients on semaglutide 2.4 mg — confirming the cardiovascular benefit is not dependent on diabetes or glucose lowering.
What This Means for Treatment Decision Making
The SELECT results elevated GLP-1 agonists from "effective weight loss drugs" to "cardiovascular risk-reducing drugs." For patients with overweight or obesity and established cardiovascular disease, semaglutide now has the same evidence basis for cardiovascular secondary prevention as statins or aspirin.
This evidence is the primary reason major cardiology organisations updated their guidelines in 2024 to recommend GLP-1 agonists as standard of care for appropriate patients — not just for weight loss.
The Pakistan Cardiovascular Context
Pakistan has one of the world's highest rates of cardiovascular disease — particularly premature heart disease in males aged 40 to 60 — driven by high rates of type 2 diabetes, hypertension, visceral obesity, and sedentary lifestyles. The populations in Pakistan who would most benefit from GLP-1 cardiovascular protection are also those who cannot access pharmaceutical semaglutide.
METASLIM addresses the GLP-1 pathway through a physician-guided sublingual program. The metabolic and weight improvements achievable through GLP-1 pathway support reduce the cardiovascular risk factors that drive Pakistan's high CVD rates — providing meaningful benefit within accessible treatment options.